Featured Research

from universities, journals, and other organizations

The Fabled Myrrh May Fight Cholesterol

Date:
October 25, 2000
Source:
University Of Pennsylvania Medical Center
Summary:
The extract from a tree in the fabled myrrh family is being investigated by researchers at the University of Pennsylvania School of Medicine for properties that may lower cholesterol.

The extract from a tree in the fabled myrrh family is being investigated by researchers at the University of Pennsylvania School of Medicine for properties that may lower cholesterol.

Dr. Philippe Szapary, Assistant Professor of Medicine at Penn who writes frequently about the use of alternative medicine in treating cardiovascular disease, is in the midst of a study of the dietary supplement gugulipid, an extract from the gummy resin of the thorny mukul myrrh bush of western India that has made its way into American health-food stores.

The bitter-tasting, fragrant myrrh is used in incense and perfumes – in the Christian tradition, a form of sweet-scented myrrh was presented by the three wise men to the infant Jesus – and the mukul myrrh, specifically, has a 2,000-year history in traditional Indian medicine. Ayurvedic health practitioners, who combine meditation, yoga and diet to address physical illness, use the resin extract in treating artherosclerosis, obesity and arthritis.

In the 1960s and ‘70s, Indian scientists were able to identify two properties of the extract – which, combined, they named gugulipid -- that appeared to aid in lowering cholesterol.

“This is something that’s been around for thousands of years, and when some scientists looked into it, they actually found a scientific basis for its effectiveness,” said Szapary. “But there’s still not enough documentation. We’re trying, in a methodical way, to establish that basis.” His work has been recognized by the National Center for Complementary and Alternative Medicine (NCCAM), which recently awarded him a five-year research grant of about $150,000 for each year.

“In this country, supplements such as gugulipid are regarded as ‘herbs’ rather than drugs, which means they aren’t currently regulated by the Food and Drug Administration,” Szapary said. “My interest is to gather enough evidence to demonstrate whether a gugulipid extract is safe and effective, in the short term, for use by Americans with mild-to-moderately elevated cholesterol.” His work with gugulipid, which began last spring, is designed to assess the drug through a simple, randomized study using 90 subjects.

Participants are divided into three groups; the first is administered a placebo, the second a standard dosage of gugulipid, and the third a higher dosage of the supplement. Each participant remains on the regimen for two months while blood tests indicate its effectiveness. Thus far 60 people have taken part.

“The participants have uniformly felt like they’ve been able to tolerate the medicine with few side effects,” he said. The study -- which began prior to Szapary’s grant from the NCCAM -- is funded in part by the General Clinical Research Center at Penn, which, in turn, is funded by the National Institutes of Health, and by the Sabinsa Corp., a manufacturer of gugulipid.

Editor’s note: Dr. Szapary has no financial interest in the Sabinsa corporation.


Story Source:

The above story is based on materials provided by University Of Pennsylvania Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Pennsylvania Medical Center. "The Fabled Myrrh May Fight Cholesterol." ScienceDaily. ScienceDaily, 25 October 2000. <www.sciencedaily.com/releases/2000/10/001025072356.htm>.
University Of Pennsylvania Medical Center. (2000, October 25). The Fabled Myrrh May Fight Cholesterol. ScienceDaily. Retrieved September 20, 2014 from www.sciencedaily.com/releases/2000/10/001025072356.htm
University Of Pennsylvania Medical Center. "The Fabled Myrrh May Fight Cholesterol." ScienceDaily. www.sciencedaily.com/releases/2000/10/001025072356.htm (accessed September 20, 2014).

Share This



More Health & Medicine News

Saturday, September 20, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Sierra Leone's Nationwide Ebola Curfew Underway

Sierra Leone's Nationwide Ebola Curfew Underway

Newsy (Sep. 20, 2014) Sierra Leone is locked down as aid workers and volunteers look for new cases of Ebola. Video provided by Newsy
Powered by NewsLook.com
Changes Found In Brain After One Dose Of Antidepressants

Changes Found In Brain After One Dose Of Antidepressants

Newsy (Sep. 19, 2014) A study suggest antidepressants can kick in much sooner than previously thought. Video provided by Newsy
Powered by NewsLook.com
Could Grief Affect The Immune Systems Of Senior Citizens?

Could Grief Affect The Immune Systems Of Senior Citizens?

Newsy (Sep. 19, 2014) The study found elderly people are much more likely to become susceptible to infection than younger adults going though a similar situation. Video provided by Newsy
Powered by NewsLook.com
Jury Delivers Verdict in Salmonella Trial

Jury Delivers Verdict in Salmonella Trial

AP (Sep. 19, 2014) A federal jury has convicted three people in connection with an outbreak of salmonella poisoning five years ago that sickened hundreds of people and was linked to a number of deaths. (Sept. 19) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins